Zero.
Samumed Sm04554 Results Normalized To Baseline
- Thread starter hypetraintime
- Start date
Like I said, not a lightweight company! These guys are developing real therapeutics.SM04554 targets CLK and DYRK.
Seems like Samumed's other compound, SM08502 is a CLK inhibitor targeting Gastrointestinal Tumors.
The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models - PubMed
The Wnt/β-catenin signaling pathway is aberrantly activated in colorectal (CRC) and many other cancers, and novel strategies for effectively targeting it may be needed due to its complexity. In this report, SM08502, a novel small molecule in clinical development for the treatment of solid...pubmed.ncbi.nlm.nih.gov
Samumed also has a DYRK1A inhibitor compound; SM07883. A potential treatment for Alzheimer.
Error - Cookies Turned Off
onlinelibrary.wiley.com
Their knee osteoarthritis treatment, lorecivivint works by inhibiting CLK2 and DYRK1A.
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment - PubMed
Lorecivivint inhibition of CLK2 and DYRK1A suggested a novel mechanism for Wnt pathway inhibition, enhancing chondrogenesis, chondrocyte function, and anti-inflammation. Lorecivivint shows potential to modify structure and improve symptoms of knee OA.
- Reaction score
- 455
The results are very good. I think you don't know how to read the reports, honestly
- Reaction score
- 455
The decrease was in the 0.025%, the 0.15% is the good one. But yeah, there's not miracle drug. It will be an addition as you said. But without the side effects. Probabbly a better minoxdill
- Reaction score
- 199
But we are part of the optimal population. So why bother looking at the graph that does not give us the most meaningful data?
They value themselves at 12 billion, it's not an independent valuation so take that for what it's worth which is nothing. The CEO admits that if they did an IPO the market wouldn't value them at anything close to 12 billion. None of their drug candidates have proven to be successful yet, and this one is still questionable. Samumed seems more like the next Theranos than the next Regeneron. The CEO is a slick salesman, but I don't trust them.
Well, < 45 years old and NW4 is not that "hand selected" to give a desirable outcome.
Even minoxidil and finasteride will significantly vary their efficacy depending on the severity of the hair loss. It's not like they created an optimal population of NW1/2 in their twenties.
Furthermore, the trend is clearly positive and it it's possible it will continue to grow hair after 3 months.
We need data from a longer period of time to judge its efficacy.
"Samumed might present Phase III at the Incos congress (11-14 March): https://www.indercos.org/
They gave a presentation about their Phase II results at the same congress in 2019."
Here's a comment i've found in the comment section of the latest article from follicle thought.
Connecting the dots with the tweet from samumed where they said they would present data to a medical congress, and considering they took roughly two months in the past to release results, this could be accurate.
They gave a presentation about their Phase II results at the same congress in 2019."
Here's a comment i've found in the comment section of the latest article from follicle thought.
Connecting the dots with the tweet from samumed where they said they would present data to a medical congress, and considering they took roughly two months in the past to release results, this could be accurate.
Guys, is it normal that I don't find the Samumed presentation on the program of Indercos ?
Then maybe it's a different conference
You'd liken a company that has multiple drugs in phase 3 and other stages of actual human trials to a complete fraudulent company? You're free to have whatever opinion you'd like but I'm just letting you know that it's a bad take. Most drug candidates fail the clinic trial process for various reasons, it doesn't make it fraud.
It's a CEOs job to be the companies hypeman lol, it gets them notoriety and funding/partnership opportunities, and a self/equity based valuation isn't worth nothing, just less then a market driven one.
Last edited:
So you think startups operate on a binary of completely legit or complete fraud with nothing in the middle. You're free to have whatever opinion you'd like but I'm just letting you know that it's a bad take. I've yet to see a successful phase 3 from Samumed. Until that happens they aren't worth 12 billion. I'm not saying they don't have real drugs with potential, but I think they're more interested in running trials just to raise funds than to actually get their drugs approved. There's no evidence that they truly believe any of their drug candidates will be successful. They don't need them to be, they're already getting rich off of dumb investors. If you feel so strongly about them go be one of those investors. Venture capital won't touch them.
RU58841 showed greater clinical efficacy than SM, but Prostrakan valued the market at less than 200 million. Samumed's drug will not be able to match the results of minoxidil, which is off-patent. There's a good chance it never comes to market, in which case it's not worth anything, just like their osteoarthritis drug that failed.
Again, I didn't say it was a fraud. Stop putting words in my mouth. If your investing strategy is to follow people who you think are good investors, then you're going to go bankrupt. Do I need to post a list of the "smart" people who invested in Enron? I'm seeing the same arguments in this thread that people used to use in the Brotzu thread. "ZOMG you're an idiot pegasus, Fidia is a huge company they wouldn't back a loser, and Dr. Brotzu is a respected doctor, he would never risk his reputation on a fraud."With a PhD in Engineering from Cambridge University, he certainly knows what he is investing in. Vickers has become one of the best-performing funds in the world.
"Over the years, we realized that risk can be split into three," Tan said. “Will the technology work?
finian fan, a world famous investor. He only invests in technologies that he understands. He seems to think highly of Samumed. it is definitely not a fraud. think it will be a very positive surprise. the phase 3 study will blow many people away
Long-term value comes from profitability, says Vickers Venture Partners' Dr. Finian Tan
In Venture Matters TV episode 8, Dr. Finian Tan, founder and chairman of Vickers Venture Partners, shared insights on the Chinese market and on what defines long-term value.kr-asia.com
Samumed's cancer drugs have more potential than this. Maybe one of them will be a success, and the company will make it big. Even in that event, that doesn't mean anything for their hair loss drug. This drug has to be evalueted on its own merits, and those merits don't justify the hope I'm seeing from some of you guys.
Last edited:
I really want the results of those damn trials...
Maybe even more than SM's results
- Reaction score
- 177
If there is any field where I would expect Theranos style grifting it would be the fkn Wild West snake oil infested hair loss field
Based on what evidence though, is my point. They are doing what literally any start-up biotech company does, ever, developing a platform in which they can expand into a pipeline and eventually push drugs to market or get acquired. I would understand the hesitancy if this was pre-clinical research, but with basically half their core pipeline in the clinic and already moved passed safety trials they are already putting their money where their mouth is by driving drugs to market.
I also don't really understand why you are saying VCs wont touch them, they raised almost 500 million in 2018 through private equity/VC in addition to 200~ million a year or two prior.
Yeah but this is my point, they have 8 programs in clinical trials right now. 1 is hairloss, the rest is cancer, degenerative disk disease, pulmonary fibrosis, tumors and alzheimer's, meaning that the science behind their WNT pathway program has been thoroughly proven to have merit behind just a single application.
This isn't a start-up pretending they can cure hairloss because their compound used on a mouse grew hair. Even if the drug doesn't prove to be worth it or effective, it's not snake oil.
Last edited: